Ergot Alkaloid Pharmacology

Correct Answer

A — Cabergoline

Rationale

Cabergoline has largely replaced bromocriptine as the preferred dopaminergic ergot for hyperprolactinemia. It has a much longer half-life than bromocriptine, allowing twice-weekly rather than daily dosing. It is better tolerated, with substantially less nausea and orthostatic hypotension at the doses used for prolactin suppression. Efficacy for prolactinoma shrinkage is comparable or superior to bromocriptine. Pergolide was a dopaminergic ergot used primarily in Parkinson disease but was withdrawn from the United States market in 2007 because of cardiac valvulopathy risk. Dihydroergotamine is a migraine ergot with no role in hyperprolactinemia. Methylergonovine is an obstetric uterotonic with no dopaminergic therapeutic indication.

Correct Answer

D — Withdrawn from the market in 2007 because of cardiac valvulopathy risk judged unacceptable given the availability of safer alternatives

Rationale

Pergolide was a dopaminergic ergot alkaloid used primarily as an adjunct in Parkinson disease. It was withdrawn from the United States market in 2007 specifically because of its cardiac valvulopathy risk — a class effect of dopaminergic ergots mediated through serotonin type 2B receptor agonism on cardiac valve interstitial cells, which stimulates fibroblast proliferation and collagen deposition. This risk was judged unacceptable because safer non-ergot dopamine agonists such as pramipexole and ropinirole were available for Parkinson disease treatment without the valvulopathy risk. Pergolide is not available through any restricted access program and has no current approved indication in the United States.

Correct Answer

B — First-line pharmacological agent for symptomatic hyperprolactinemia from any cause

Rationale

Bromocriptine is classified as a first-line pharmacological agent for symptomatic hyperprolactinemia regardless of the underlying cause — whether from a prolactin-secreting pituitary adenoma, medication-induced hyperprolactinemia from dopamine receptor blockers, or idiopathic causes. At standard doses it normalizes serum prolactin, restores menstrual cycles, and resolves galactorrhea in most patients. In patients with prolactinomas it also shrinks the tumor in many cases — a property that makes dopamine agonist therapy the primary treatment for prolactinomas rather than surgery. Cabergoline is now preferred over bromocriptine in most clinical settings because of better tolerability, but bromocriptine established the first-line pharmacological role for this drug class. Bromocriptine is not restricted to post-surgical patients, is not an adjunct to somatostatin analogs, and is not limited to macroprolactinomas.

Correct Answer

A — Dopamine receptor blockade — typically from initiation or dose escalation of antipsychotic drugs

Rationale

Neuroleptic malignant syndrome results from abrupt, widespread blockade of dopamine receptors in the brain and spinal cord. This occurs most commonly after initiation or dose escalation of antipsychotic drugs, which are dopamine type 2 receptor antagonists. The resulting loss of dopaminergic signaling in motor circuits produces the severe muscle rigidity, and in thermoregulatory circuits produces the hyperthermia that characterizes the syndrome. Understanding that the cause is dopamine receptor blockade — not stimulation — is essential because the pharmacological treatment involves restoring dopaminergic tone with a dopamine agonist such as bromocriptine. Serotonin receptor overstimulation describes serotonin syndrome, a distinct toxidrome with a different clinical presentation and treatment. Acetylcholine excess describes cholinergic toxidrome from anticholinesterase poisoning.

Correct Answer

C — Adjunct to levodopa or early monotherapy in selected patients, though largely replaced by pramipexole and ropinirole in current practice

Rationale

Bromocriptine acts as a dopamine agonist in the basal ganglia, directly stimulating dopamine type 2 receptors on striatal neurons and partially compensating for the loss of endogenous dopamine in Parkinson disease. It is used as an adjunct to levodopa in patients whose motor control is not adequately managed by levodopa alone, and as an early monotherapy in patients for whom levodopa initiation is being delayed. However, bromocriptine is less effective in Parkinson disease than the newer, more selective non-ergot dopamine agonists — pramipexole and ropinirole — which have largely replaced it in this indication. Bromocriptine is not the preferred first-line agent over levodopa, does not replace levodopa in advanced disease, and has no established neuroprotective role in slowing neurodegeneration.

Correct Answer

D — Serotonin type 2B receptors on cardiac valve interstitial cells

Rationale

The cardiac valvulopathy associated with dopaminergic ergot alkaloids is mediated through serotonin type 2B receptors on cardiac valve interstitial cells. Activation of these receptors stimulates fibroblast proliferation and collagen deposition, producing thickening and stiffening of the valve leaflets. This is a class effect of the ergot backbone — bromocriptine, cabergoline, and the now-withdrawn pergolide all carry this risk. Non-ergot dopamine agonists such as pramipexole and ropinirole do not have serotonin type 2B receptor activity and therefore do not produce this valvulopathy. The distinction is pharmacologically important: the valvulopathy risk is not a consequence of dopamine type 2 receptor agonism itself but of the serotonin type 2B receptor activity retained from the ergot backbone. Alpha-adrenergic receptors, dopamine type 2 receptors, and serotonin type 1B receptors are not the receptors responsible for this adverse effect.

Correct Answer

B — Bromocriptine activates dopamine type 2 receptors on anterior pituitary lactotrophs, mimicking the tonic inhibitory action of hypothalamic dopamine and suppressing prolactin secretion

Rationale

In the anterior pituitary, lactotroph cells secrete prolactin under tonic inhibitory control by dopamine released from hypothalamic neurons into the portal circulation. Dopamine activates dopamine type 2 receptors on lactotrophs and continuously suppresses prolactin release. When hypothalamic dopamine release is reduced or when dopamine receptors are blocked — as with antipsychotic drugs — prolactin secretion rises. Bromocriptine mimics this endogenous inhibitory mechanism by acting directly as a dopamine type 2 receptor agonist on lactotrophs, suppressing prolactin secretion regardless of the state of hypothalamic dopamine release. This makes it effective for hyperprolactinemia from any cause. Bromocriptine does not block peripheral prolactin receptors, does not stimulate hypothalamic dopamine release, and does not inhibit prolactin biosynthetic enzymes.

Correct Answer

D — Dopamine type 2 receptor activation on lactotroph cells inhibits both prolactin secretion and lactotroph cell proliferation, simultaneously reducing hormone output and tumor mass

Rationale

The dopamine type 2 receptor on lactotroph cells regulates both the secretory function — release of prolactin — and the proliferative function — cell division and tumor growth. When bromocriptine activates this receptor, it suppresses prolactin release through its secretory inhibitory effect, and simultaneously inhibits lactotroph proliferation through its antiproliferative effect. The result is a dual benefit unique to dopamine agonist therapy: lowering prolactin levels and shrinking the tumor itself. This property distinguishes bromocriptine and cabergoline from most other endocrine tumor treatments, which typically suppress hormone secretion without reducing tumor mass. The tumor shrinkage is not mediated by pituitary vasoconstriction, immune surveillance activation, or removal of a prolactin autocrine signal.

Correct Answer

A — Dopamine receptor blockade in basal ganglia and spinal cord motor circuits causes severe muscle rigidity; continuous isometric muscle contraction generates heat that overwhelms thermoregulatory capacity

Rationale

The hyperthermia of neuroleptic malignant syndrome is mechanistically linked to muscle rigidity, not to a primary defect in central thermoregulation. Widespread dopamine receptor blockade by antipsychotic drugs removes dopaminergic inhibition from motor circuits in the basal ganglia and spinal cord, producing intense, continuous muscle rigidity throughout the body. This sustained isometric muscle contraction generates large amounts of heat as a metabolic byproduct, and when the rigidity is severe enough, the heat generation exceeds the body's capacity to dissipate it, producing the extreme hyperthermia. This mechanistic link explains why reducing muscle rigidity — through dantrolene blockade of sarcoplasmic reticulum calcium release or through bromocriptine restoration of dopaminergic motor circuit tone — also lowers body temperature. Direct hypothalamic set-point elevation, mitochondrial uncoupling by antipsychotics in muscle, and sympathoadrenal catecholamine-driven brown adipose thermogenesis are not the established mechanisms of neuroleptic malignant syndrome hyperthermia.

Correct Answer

C — Bromocriptine, as a dopamine type 2 receptor agonist, competes with the blocking antipsychotic for receptor occupancy and partially reverses the dopamine receptor blockade driving the syndrome

Rationale

Neuroleptic malignant syndrome is driven by widespread dopamine receptor blockade. Bromocriptine reverses this by acting as a dopamine type 2 receptor agonist — it binds the same receptors the antipsychotic is blocking and activates them, partially restoring dopaminergic signaling in the motor circuits of the basal ganglia and spinal cord. This restoration of dopaminergic tone reduces muscle rigidity, which in turn reduces heat generation and lowers body temperature. Bromocriptine is used alongside dantrolene, which addresses the muscle component directly by blocking calcium release from the sarcoplasmic reticulum, regardless of the neurological cause of the rigidity. Bromocriptine does not accelerate antipsychotic metabolism through cytochrome P450 induction, does not block serotonin type 2A receptors, and does not act at the motor end plate calcium channels.

Correct Answer

B — Dantrolene blocks calcium release from the sarcoplasmic reticulum in skeletal muscle, directly reducing muscle contraction and heat production regardless of the neurological cause of the rigidity

Rationale

The combination of bromocriptine and dantrolene addresses neuroleptic malignant syndrome at two separate levels. Bromocriptine acts centrally at the dopamine type 2 receptor — restoring dopaminergic tone in motor circuits and reducing the neurological drive to rigidity. Dantrolene acts peripherally in skeletal muscle — it blocks the ryanodine receptor responsible for calcium release from the sarcoplasmic reticulum, preventing the calcium influx that triggers actin-myosin crossbridge cycling and muscle contraction. Because dantrolene's mechanism is at the level of the muscle cell itself, it reduces rigidity and heat generation directly, regardless of what neurological signals are driving the muscle. This two-level approach addresses the syndrome at the receptor (bromocriptine) and at the effector organ (dantrolene) simultaneously. Dantrolene does not act through alpha-adrenergic receptors on vasculature, dopamine type 2 receptors at the neuromuscular junction, or gamma-aminobutyric acid receptors in the spinal cord.

Correct Answer

D — Dopamine type 2 receptor activation in the cardiovascular system reduces sympathetic tone, impairing the compensatory vasoconstriction and heart rate increase needed to maintain blood pressure on standing

Rationale

When a person moves from supine to standing, gravity causes venous pooling in the lower extremities and reduces cardiac preload. The normal compensatory response involves sympathetic activation — increased heart rate and peripheral vasoconstriction — to maintain blood pressure. Bromocriptine's dopamine type 2 receptor agonism in the cardiovascular system reduces this sympathetic outflow, impairing the compensatory response. The result is a fall in blood pressure on standing — orthostatic hypotension. This adverse effect is particularly prominent when bromocriptine therapy is initiated and tends to diminish with continued use as the cardiovascular system adapts. Starting at low doses and titrating slowly reduces but does not eliminate this problem. Paradoxical venous vasodilation through alpha-adrenergic activation, baroreceptor blunting through serotonin type 2 receptors, and renin inhibition through juxtaglomerular dopamine type 2 receptors each represent pharmacological mechanisms distinct from the sympathetic tone reduction responsible for bromocriptine-induced orthostatic hypotension.

Correct Answer

A — Serotonin type 2B receptor agonism from the ergot backbone stimulates fibroblast proliferation and collagen deposition on cardiac valve interstitial cells, thickening and stiffening the valve leaflets

Rationale

The cardiac valvulopathy risk of dopaminergic ergots is attributable to their serotonin type 2B receptor activity, which is retained from the lysergic acid backbone. Cardiac valve interstitial cells express serotonin type 2B receptors, and when these receptors are chronically activated, fibroblasts proliferate and deposit collagen, progressively thickening and stiffening the valve leaflets. This process leads to the restrictive valve disease observed with long-term use of ergot-derived dopamine agonists, particularly at the higher doses used in Parkinson disease. Non-ergot dopamine agonists — pramipexole and ropinirole — do not have meaningful serotonin type 2B receptor activity and therefore do not produce this adverse effect. The distinction is critical when choosing between agents for long-term dopaminergic therapy. Dopamine type 2 receptor-mediated collagen synthesis, alpha-adrenergic ischemic fibrosis, and autoimmune mechanisms are not the established basis for this class-specific valvulopathy.

Correct Answer

C — Dopamine type 2 receptor activation in the chemoreceptor trigger zone of the medulla stimulates the vomiting center, producing nausea and vomiting as a predictable pharmacological effect

Rationale

The nausea produced by bromocriptine results from its primary pharmacological mechanism — dopamine type 2 receptor agonism — acting at the chemoreceptor trigger zone, a specialized area in the medulla oblongata that detects emetic stimuli and activates the vomiting center. This adverse effect is not a consequence of bromocriptine's ergot backbone activities but of its intended dopaminergic action at an unintended anatomical site. The same receptor type bromocriptine uses therapeutically in the pituitary and basal ganglia is present in the chemoreceptor trigger zone and produces an unwanted emetic response when activated. Starting therapy at low doses and titrating slowly reduces but does not eliminate nausea for most patients. Enterochromaffin serotonin release, mesenteric vasoconstriction causing visceral ischemia, and gastric smooth muscle dopamine type 2 receptor-mediated gastroparesis each describe gastrointestinal mechanisms that operate through pathways distinct from the chemoreceptor trigger zone activation responsible for bromocriptine-induced nausea.

Correct Answer

B — A dopamine type 2 receptor agonist, because activating dopamine receptors on lactotrophs suppresses prolactin secretion and inhibits tumor cell proliferation, reducing both hormone levels and tumor size

Rationale

Dopamine agonists — bromocriptine and the preferred cabergoline — are the first-line pharmacological treatment for prolactinoma. Their mechanism addresses both therapeutic goals simultaneously: dopamine type 2 receptor activation on lactotroph cells suppresses prolactin secretion through its secretory inhibitory effect, and inhibits lactotroph cell proliferation through its antiproliferative effect, causing the tumor to shrink in many patients. This dual action distinguishes dopamine agonist therapy from most other endocrine tumor treatments, which suppress hormone output without reducing tumor mass. For this patient with a microprolactinoma and no mass effect, dopamine agonist therapy is the appropriate primary treatment. Somatostatin analogs are used for growth hormone-secreting tumors (acromegaly) and are considerably less effective for prolactinomas. Estrogen receptor antagonists and gonadotropin-releasing hormone antagonists do not target the dopaminergic mechanism driving lactotroph hypersecretion and proliferation.

Correct Answer

D — Bromocriptine, because as a dopamine type 2 receptor agonist it competes with haloperidol for receptor occupancy and partially reverses the dopamine receptor blockade driving the rigidity and hyperthermia

Rationale

After discontinuing the offending antipsychotic, the pharmacological treatment of neuroleptic malignant syndrome targets the dopamine receptor blockade that is driving the syndrome. Bromocriptine, as a dopamine type 2 receptor agonist, competes with haloperidol for receptor occupancy in the basal ganglia and spinal cord motor circuits. By activating these receptors, bromocriptine partially restores the dopaminergic signaling that haloperidol has blocked, reducing the motor circuit dysregulation responsible for the severe muscle rigidity. Reduced rigidity decreases heat generation from continuous isometric muscle contraction, lowering body temperature. In severe cases, dantrolene is added alongside bromocriptine to address the muscle component directly — but dantrolene alone does not restore dopaminergic tone and is not sufficient as the sole pharmacological intervention. Reintroducing haloperidol at lower doses would perpetuate the dopamine receptor blockade, and levodopa acts as a dopamine precursor rather than a direct receptor agonist competing for the blocked sites.

Correct Answer

A — Excessive dopaminergic stimulation of limbic circuits at the high doses required for Parkinson disease motor control produces hallucinations and confusion as dose-dependent adverse effects

Rationale

The hallucinations and confusion that develop in some patients taking bromocriptine for Parkinson disease reflect excessive dopaminergic stimulation in limbic circuits. The doses of bromocriptine needed to provide meaningful motor benefit in Parkinson disease are substantially higher than those used for hyperprolactinemia, and at these higher doses, dopamine type 2 receptor agonism extends beyond the intended basal ganglia motor circuits to limbic and mesolimbic pathways that regulate perception, mood, and cognition. Dopaminergic overstimulation in these circuits produces the hallucinations, delusions, and confusion observed in susceptible patients — particularly those with pre-existing cognitive impairment or dementia, who are more vulnerable to these effects at lower doses. These are dose-dependent adverse effects of the drug's primary dopaminergic mechanism, not consequences of serotonin type 2B receptor fibrosis in the brain, alpha-adrenergic cerebrovascular constriction, or anticholinergic cholinergic neuron inhibition.

Correct Answer

C — Serotonin type 2B receptor agonism from cabergoline's ergot backbone stimulates fibroblast proliferation and collagen deposition on cardiac valve interstitial cells, producing fibrosis and thickening of the valve leaflets

Rationale

Cabergoline retains serotonin type 2B receptor activity from its lysergic acid backbone, despite being classified primarily as a dopamine type 2 receptor agonist. Cardiac valve interstitial cells express serotonin type 2B receptors, and chronic activation of these receptors stimulates fibroblast proliferation and collagen deposition — the same fibrotic mechanism seen with other serotonin type 2B agonists. Progressive collagen accumulation thickens and stiffens the valve leaflets, impairing their normal mobility and producing the restrictive valvulopathy found on this patient's echocardiogram. The risk is dose-dependent and is most clinically relevant at the high doses required for Parkinson disease motor control — substantially higher than the doses used for hyperprolactinemia, at which the cardiac risk is considered low. Non-ergot dopamine agonists such as pramipexole and ropinirole lack serotonin type 2B activity and do not produce this complication. This is why periodic echocardiographic monitoring is recommended for patients taking dopaminergic ergots at Parkinson disease doses. Dopamine type 2 receptor-mediated collagen synthesis, ischemic fibrosis from alpha-adrenergic coronary constriction, and autoimmune valve disease are not the mechanism of this finding.